{
    "id": 3681,
    "fullName": "DNMT3A mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "DNMT3A mutant indicates an unspecified mutation in the DNMT3A gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1788,
        "geneSymbol": "DNMT3A",
        "terms": [
            "DNMT3A",
            "DNMT3A2",
            "HESJAS",
            "M.HsaIIIA",
            "TBRS"
        ]
    },
    "variant": "mutant",
    "createDate": "03/11/2015",
    "updateDate": "09/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7518,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to patients with wild-type DNMT3A when treated with frontline hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649).",
            "molecularProfile": {
                "id": 3485,
                "profileName": "DNMT3A mutant"
            },
            "therapy": {
                "id": 650,
                "therapyName": "Decitabine",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6396,
                    "pubMedId": 27418649,
                    "title": "Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27418649"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3571,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448).",
            "molecularProfile": {
                "id": 3485,
                "profileName": "DNMT3A mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5345,
                    "pubMedId": 22490330,
                    "title": "Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22490330"
                },
                {
                    "id": 5346,
                    "pubMedId": 21881046,
                    "title": "Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21881046"
                },
                {
                    "id": 5347,
                    "pubMedId": 21670448,
                    "title": "Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21670448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15944,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pinometostat (EPZ-5676) treatment of acute myeloid leukemia cell lines and xenografts resulted in apoptosis, cell-cycle arrest, and terminal differentiation (PMID: 27335278).",
            "molecularProfile": {
                "id": 3485,
                "profileName": "DNMT3A mutant"
            },
            "therapy": {
                "id": 2855,
                "therapyName": "Pinometostat",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14060,
                    "pubMedId": 27335278,
                    "title": "DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27335278"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18956,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "DNMT3A mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 3485,
                "profileName": "DNMT3A mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 111147,
                "name": "angioimmunoblastic T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3573,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a retrospective analysis, the combination of DNMT3A, FLT3, and NPM1 mutations in patients with acute myeloid leukemia was highly associated with decreased event-free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).",
            "molecularProfile": {
                "id": 28949,
                "profileName": "DNMT3A mut FLT3 mut NPM1 mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3849,
                    "pubMedId": 25281355,
                    "title": "Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25281355"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16475,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of FLT3-ITD , DNMT3A, and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31609,
                "profileName": "DNMT3A mut FLT3 exon 14 ins NPM1 mut"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16469,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of FLT3-ITD, DNMT3A, and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31609,
                "profileName": "DNMT3A mut FLT3 exon 14 ins NPM1 mut"
            },
            "therapy": {
                "id": 2522,
                "therapyName": "Entospletinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16359,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-539 treatment resulted in clearance of leukemia cells in patient-derived xenograft (PDX) models of acute myeloid leukemia harboring mutations in NPM1, DNMT3, and FLT3 exon 14 (ITD) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).",
            "molecularProfile": {
                "id": 31609,
                "profileName": "DNMT3A mut FLT3 exon 14 ins NPM1 mut"
            },
            "therapy": {
                "id": 8006,
                "therapyName": "KO-539",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14464,
                    "pubMedId": null,
                    "title": "A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/LB-A27"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16468,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of DNMT3A and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31639,
                "profileName": "DNMT3A mut NPM1 mut"
            },
            "therapy": {
                "id": 2522,
                "therapyName": "Entospletinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16472,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of DNMT3A and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31639,
                "profileName": "DNMT3A mut NPM1 mut"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3485,
            "profileName": "DNMT3A mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28949,
            "profileName": "DNMT3A mut FLT3 mut NPM1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31609,
            "profileName": "DNMT3A mut FLT3 exon 14 ins NPM1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31639,
            "profileName": "DNMT3A mut NPM1 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}